Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early‐stage, favorable Hodgkin lymphoma
Open Access
- 3 November 2003
- Vol. 98 (11), 2393-2401
- https://doi.org/10.1002/cncr.11807
Abstract
BACKGROUND The acknowledged effectiveness of vinblastine, bleomycin, and methotrexate (VBM) chemotherapy in patients with early‐stage Hodgkin lymphoma has been associated with conflicting toxicity reports. METHODS One hundred forty‐three patients were evaluated clinically and had favorable Stage IA or IIA Hodgkin lymphoma. Ninety‐three patients were treated with the standard VBM schedule combined with extended‐field radiotherapy (EF‐RT), leaving the choice of the therapeutic sequence free. Fifty subsequent patients were treated with a slightly modified VBM schedule (VbMp) combined with RT limited to involved fields (IF‐RT) and delivered only after the end of chemotherapy. In the VbMp schedule, intervals between cycles were 21 days instead of 28 days, bleomycin doses were reduced, small doses of prednisone were given orally, and the interval before RT was prolonged. RESULTS Clinical response was complete in 96% of patients who were treated with VBM plus EF‐RT and in 94% of patients who were treated with VbMp plus IF‐RT. Recurrence rates were nearly identical (12% and 11%, respectively) over necessarily different follow‐up (91 months and 33 months, respectively). Hematologic toxicity was tolerable in both trials, and pulmonary side effects were moderate in the first trial and negligible in the second. On the whole, treatment was tolerated better when RT followed chemotherapy. CONCLUSIONS The VBM regimen was confirmed to be effective in patients with early‐stage Hodgkin lymphoma. Administration of all cycles before RT improved tolerance; pulmonary toxicity probably is mitigated further by reduced bleomycin doses, mild prednisone therapy, and a more prolonged resting interval before RT. A slightly higher recurrence rate was expectable in the VBM plus IF‐RT trial despite the actual intensification of vinblastine and methotrexate. Cancer 2003. © 2003 American Cancer Society.Keywords
Funding Information
- Ministero dell'Università (Rome, Italy)
- Adolfo Ferrata e Edoardo Storti Foundation (Pavia, Italy)
This publication has 17 references indexed in Scilit:
- British National Lymphoma Investigation: Pilot Studies of Neoadjuvant Chemotherapy in Clinical Stage Ia and IIa Hodgkin's DiseaseClinical Oncology, 2001
- Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation.Journal of Clinical Oncology, 1997
- Should Poor Risk Patients with Hodgkin's Disease be Sorted out for Intensive Treatments?Leukemia & Lymphoma, 1995
- Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's diseaseAnnals Of Oncology, 1994
- Efficacy and toxicity of vinblastine, bleomycin, and methotrexate with involved-field radiotherapy in clinical stage IA and IIA Hodgkin's disease: a British National Lymphoma Investigation pilot study.Journal of Clinical Oncology, 1994
- Reporting outcomes in Hodgkin's disease and lymphoma.Journal of Clinical Oncology, 1987
- Toxicity and response criteria of the Eastern Cooperative Oncology GroupAmerican Journal of Clinical Oncology, 1982
- Treatment of hodgkin's disease using intensive chemotherapy followed by irradiationInternational Journal of Radiation Oncology*Biology*Physics, 1976
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958